Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE)

Core Insights - Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is recognized as a promising biotech stock with significant potential [1] - Bank of America Securities analyst Tazeen Ahmad has maintained a Buy rating on Ultragenyx and set a price target of $79.00 [1] Financial Performance - For fiscal Q2 2025, Ultragenyx reported total revenue of $166 million, with Crysvita® generating $120 million and Dojolvi® contributing $23 million [2] - The company reaffirmed its 2025 revenue guidance, now expecting total revenue in the range of $640 million to $670 million [2] Product Portfolio - Ultragenyx focuses on developing, acquiring, and commercializing novel products aimed at treating genetic diseases [2] - The company's product portfolio includes Crysvita, Mepsevii, Dojolvi, and Evkeeza [2]